Literature DB >> 22421124

Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Sharon R Hymes1, Amin M Alousi, Edward W Cowen.   

Abstract

Dermatologists are ideally suited to manage the various cutaneous sequelae of graft-versus-host disease (GVHD) outlined in part I of this review. However, the complexity of the patient with GVHD, including comorbidities, potential drug interactions related to polypharmacy, and the lack of evidence-based treatment guidelines, are significant challenges to optimizing patient care. In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22421124      PMCID： PMC7357210          DOI： 10.1016/j.jaad.2011.11.961

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  130 in total

1.  Toxic absorption of tacrolimus [corrected] in a patient with severe acute graft-versus-host disease.

Authors:  D L Neuman; J E Farrar; J M Moresi; G B Vogelsang; M A Higman
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

2.  Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis in rat vascular smooth muscle cells.

Authors:  J Park; H Ha; H J Ahn; S-W Kang; Y S Kim; J Y Seo; M S Kim
Journal:  Transplant Proc       Date:  2005-10       Impact factor: 1.066

3.  Detection of human papillomavirus in multiple eccrine poromas in a patient with chronic graft-vs-host disease and immunosuppression.

Authors:  Melissa L Diamantis; Heather M Richmond; Peter L Rady; Stephen K Tyring; Jonathan E Cutlan; Carlos Torres-Cabala; Sharon R Hymes
Journal:  Arch Dermatol       Date:  2011-01

4.  Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

Authors:  Daniel Wolff; Armin Gerbitz; Francis Ayuk; Alexander Kiani; Gerhard C Hildebrandt; Georgia B Vogelsang; Sharon Elad; Anita Lawitschka; Gerard Socie; Steven Z Pavletic; Ernst Holler; Hildegard Greinix
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-25       Impact factor: 5.742

5.  Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.

Authors:  Voravit Ratanatharathorn; Lois Ayash; Christopher Reynolds; Samuel Silver; Pavan Reddy; Michael Becker; James L M Ferrara; Joseph P Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2003-08       Impact factor: 5.742

6.  Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole.

Authors:  Edward W Cowen; Josephine C Nguyen; Daniel D Miller; Diana McShane; Sarah T Arron; Neil S Prose; Maria L Turner; Lindy P Fox
Journal:  J Am Acad Dermatol       Date:  2009-11-06       Impact factor: 11.527

7.  Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells.

Authors:  Erin Gatza; Clare E Rogers; Shawn G Clouthier; Kathleen P Lowler; Isao Tawara; Chen Liu; Pavan Reddy; James L M Ferrara
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

8.  Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

Authors:  John E Levine; Sophie Paczesny; Shin Mineishi; Thomas Braun; Sung W Choi; Raymond J Hutchinson; Dawn Jones; Yasser Khaled; Carrie L Kitko; Daniel Bickley; Oleg Krijanovski; Pavan Reddy; Gregory Yanik; James L M Ferrara
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

9.  Rippled skin, fasciitis, and joint contractures.

Authors:  Asha R Patel; Daniele Avila; Harry L Malech; Steven Z Pavletic; Larry Yao; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2008-12       Impact factor: 11.527

10.  312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions.

Authors:  M Ozawa; K Ferenczi; T Kikuchi; I Cardinale; L M Austin; T R Coven; L H Burack; J G Krueger
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307
View more
  6 in total

1.  Chronic graft-versus-host disease: clinical presentation of multiple lesions of lichenoid and atrophic pattern.

Authors:  Luiza Vasconcelos; Erica Cristina Vieira; Eliana Maria Minicucci; Ana Gabriela Salvio; Mair Pedro de Souza; Mariangela Esther Alencar Marques; Silvio Alencar Marques
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

2.  Hyperpigmented follicular papules and bullae in an immunocompromised infant.

Authors:  Jason Emer; Shaily Pandey; Brian J Marciniak; Harleen Sidhu; Robert Phelps
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

3.  The immune reconstitution of the skin following sex-mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence in situ hybridization and immunohistochemistry.

Authors:  C L Stewart; C M Cornejo; K A Wanat; I Sander; S Samimi; S Prouty; J Seykora; P Zhang; M Rosenbach; E J Kim; R G Micheletti
Journal:  Br J Dermatol       Date:  2018-01-08       Impact factor: 9.302

4.  Graft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity.

Authors:  Benjamin H Kaffenberger; Rena C Zuo; Alejandro Gru; Alisha N Plotner; Sarah A Sweeney; Steven M Devine; Sharon R Hymes; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2014-07-01       Impact factor: 11.527

Review 5.  A review of stem cell translation and potential confounds by cancer stem cells.

Authors:  Bernadette Bibber; Garima Sinha; Aline R M Lobba; Steven J Greco; Pranela Rameshwar
Journal:  Stem Cells Int       Date:  2013-12-10       Impact factor: 5.443

Review 6.  Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment.

Authors:  Karla Strong Rodrigues; Carla Oliveira-Ribeiro; Silvia de Abreu Fiuza Gomes; Robert Knobler
Journal:  Am J Clin Dermatol       Date:  2018-02       Impact factor: 7.403
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.